Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Early Height and Weight Changes in Children Using Cotrimoxazole Prophylaxis with Antiretroviral Therapy
Authors: David C. Boettiger
Dina Muktiarti
Nia Kurniati
Khanh H. Truong
Suneeta Saghayam
Penh Sun Ly
Rawiwan Hansudewechakul
Lam Van Nguyen
Viet Chau Do
Tavitiya Sudjaritruk
Pagakrong Lumbiganon
Kulkanya Chokephaibulkit
Torsak Bunupuradah
Nik Khairulddin Nik Yusoff
Dewi Kumara Wati
Kamarul Azahar Mohd Razali
Moy Siew Fong
Revathy A. Nallusamy
Annette H. Sohn
Azar Kariminia
University of New South Wales (UNSW) Australia
University of Indonesia, RSUPN Dr. Cipto Mangunkusumo
Children's Hospital 1
YR Gaitonde Centre for AIDS Research and Education
National Center for HIV/AIDS
Chiangrai Prachanukroh Hospital
National Hospital of Pediatrics Hanoi
Children's Hospital 2
Chiang Mai University
Khon Kaen University
Mahidol University
The HIV Netherlands Australia Thailand Research Collaboration
Hospital Raja Perempuan Zainab II
Universitas Udayana
Kuala Lumpur Hospital
Hospital Likas
Penang Hospital
amfAR - The Foundation for AIDS Research
Keywords: Medicine
Issue Date: 1-Nov-2016
Citation: Clinical Infectious Diseases. Vol.63, No.9 (2016), 1236-1244
Abstract: © The Author 2016. Background. The growth benefits of cotrimoxazole during early antiretroviral therapy (ART) are not well characterized. Methods. Individuals enrolled in the Therapeutics Research, Education, and AIDS Training in Asia Pediatric HIV Observational Database were included if they started ART at ages 1 month-14 years and had both height and weight measurements available at ART initiation (baseline). Generalized estimating equations were used to identify factors associated with change in height-for-age z-score (HAZ), follow-up HAZ ≥ -2, change in weight-for-age z-score (WAZ), and follow-up WAZ ≥ -2. Results. A total of 3217 children were eligible for analysis. The adjusted mean change in HAZ among cotrimoxazole and non-cotrimoxazole users did not differ significantly over the first 24 months of ART. In children who were stunted (HAZ < -2) at baseline, cotrimoxazole use was not associated with a follow-up HAZ ≥ -2. The adjusted mean change in WAZ among children with a baseline CD4 percentage (CD4%) >25% became significantly different between cotrimoxazole and non-cotrimoxazole users after 6 months of ART and remained significant after 24 months (overall P <. 01). Similar changes in WAZ were observed in those with a baseline CD4% between 10% and 24% (overall P <. 01). Cotrimoxazole use was not associated with a significant difference in follow-up WAZ in children with a baseline CD4% <10%. In those underweight (WAZ < -2) at baseline, cotrimoxazole use was associated with a follow-up WAZ ≥ -2 (adjusted odds ratio, 1.70 vs not using cotrimoxazole [95% confidence interval, 1.28-2.25], P <. 01). This association was driven by children with a baseline CD4% ≥10%. Conclusions. Cotrimoxazole use is associated with benefits to WAZ but not HAZ during early ART in Asian children.
ISSN: 15376591
Appears in Collections:Scopus 2016-2017

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.